Peripheral blood stem cell mobilization with cyclophosphamide in combination with G-CSF, GM-CSF, or sequential GM-CSF/G-CSF in non-Hodgkin's lymphoma patients: A randomized prospective study

Journal of Hematotherapy and Stem Cell Research

Volumn 9, Issue 5, 2000, Pages 737-748

  Gazitt, Y ^a   Callander, N ^a   Freytes, C O ^b   Shaughnessy, P ^a   Liu, Q ^a   Tsai, T W ^a   Devore, P ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b WILFORD HALL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; AGE; AGED; ANAMNESIS; APHERESIS; ARTICLE; CELL MOTILITY; CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; FEBRILE NEUTROPENIA; FEMALE; HISTOPATHOLOGY; HUMAN; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPHIL; NONHODGKIN LYMPHOMA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STEM CELL; STEM CELL TRANSPLANTATION; SURVIVAL; TARGET CELL; THROMBOCYTE; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, CD34; ANTIGENS, CD45; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTORS, RECOMBINANT; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0033748383     PISSN: 15258165     EISSN: None     Source Type: Journal    
DOI: 10.1089/15258160050196786     Document Type: Article

References (36)

1. Characterization of chemotherapy mobilized peripheral blood progenitor cells for use in autologous stem cell transplantation
2. Factors affecting blood stem cell collection following high dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumors
3. Transplantation potential of peripheral blood stem cells induced by G-CSF
4. Optimization of stem cell mobilization
5. Transplantation of hematopoietic cells released into the peripheral blood for non-Hodgkin's lymphoma
6. Use of granulocyte colony-stimulating factor (G-CSF) for mobilizing peripheral blood stem cells: Risk of mobilizing clonal myeloma cells in patients with bone marrow infiltration
7. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors
8. Differential mobilization of myeloma cells and normal hematopoietic stem cells in multiple myeloma after treatment with cyclophosphamide and GM-CSF
9. Purified CD34+Lin-Thy+ stem cells do not contain clonal myeloma cells
10. Factors that influence collection and engraftment of autologous peripheral blood stem cells
11. Patient characteristic associated with successful mobilization and autografting of peripheral blood progenitor cells in malignant lymphoma
12. + cell yields
13. Successful PBSC Mobilization with high dose G-CSF for patients failing a first round of mobilization
14. High-dose therapy with peripheral blood progenitor cell transplantation in non-Hodgkin's lymphoma
15. + progenitor cell collection in patients with hematological malignancies
16. Peripheral blood stem cell transplant for multiple myeloma: Identification of favorable variables for rapid engraftment in 225 patients
17. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cells collections in 692 patients after the administration of myeloablative therapy
18. Autologous transplantation with peripheral blood mononuclear cells after administration of G-CSF
19. Granulocyte colony stimulating factor mobilized peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high dose chemotherapy
20. Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: An analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma
21. Comparative effect of GM-CSF and G-CSF on priming of peripheral blood progenitor cells for use with autologous bone marrow after high dose chemotherapy
22. Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation
23. + cells mobilized by G-CSF
24. Collection, engraftment kinetics and tumor contamination of highly purified hematopoietic progenitor cells to support high dose therapy in multiple myeloma
25. Harvesting and enrichment of HPC mobilized into the peripheral blood of normal donors by GM-CSF or G-CSF: Potential role in allogeneic transplantation
26. Composition of peripheral blood progenitor cell components collected from healthy donors
27. Randomized trial of granulocyte colony stimulating factor vs. granulocyte-macro-phage colony stimulating factor vs. concurrent G-CSF plus GM-CSF for mobilization of allogeneic peripheral blood stem cells
28. Use of concurrent GM-CSF and G-CSF administration to remobilized patients who failed initial mobilization: Results on 23 patients from 2 centers
29. Phase I/II study of combined G-CSF and GM-CSF administration for the mobilization of hematopoietic progenitor cells
30. Randomized comparison of G-CSF + GM-CSV vs G-CSF alone for mobilization of peripheral blood stem cells: Effects on hematopoietic recovery after high-dose chemotherapy
31. + cell counts based on the ISHAGE guidelines
32. Isolation of a candidate human hematopoietic stem cell population
33. Expression of Thy-1 on human hematopoietic progenitor cells
34. A randomized study of peripheral blood stem cell mobilization with cyclophosphamide in combination with G-CSF, GM-CSF and sequential GM-CSF followed by G-CSF in non-Hodgkin's lymphoma patients: Co-mobilization of dendritic cells and NK-cells
35. Recombinant human granulocyte and granulocytemacrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells
36. Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies